Tissue plasminogen activator (tPA), as the first United State FDA approved cerebral infarction treatment, can be given intravenously in thrombolytic therapy within 4.5 h after the onset of stroke symptoms [33], however it is not widely used for patients in China. The gene discussed is PLAT; the disease is stroke disorder.